Deepak Singh, Amazon EC2, Life Sciences in the Cloud
Ilya Kupershmidt, co-founder Next Bio
Joel Dudley, Numedii, Data Driven drug Repurposing
The Open Science Summit unites researchers, life science industry professionals, students, patients and other stakeholders to discuss the future of collaborative science and innovation.
This, the second year, features in-depth sessions on new models for drug discovery and clinical trials, personal genomics, the patent system, the future of scientific publications, and more.
Dr. Joel Dudley
Dr. Dudley is a co-founder and Director of an innovative biopharmaceutical company leveraging informatics and big-data to enable a molecular systems based approach to discover biomarkers and match novel therapies to human disease indications. Prior to that, he was a Bioinformatics Scientist in the Division of Systems Medicine at Stanford University School of Medicine, where he drove novel research in translational bioinformatics approaches to genomic medicine.
He has published more than 25 peer-reviewed research articles on topics such as pharmacogenomics, personal genomics, and biomarker discovery featured in journals such as Lancet, Nature Biotechnology, and Nature Molecular Systems Biology. Joel's most recent work involves large-scale integration of public molecular data to enable systems approaches to drug repositioning and biomarker discovery.
Mr. Kupershmidt leads NextBio's product, scientific computing and content groups. His team includes PhDs and MDs from leading academic institutions with extensive experience in genomics, computational biology and clinical research. Mr. Kupershmidt has a decade of experience in the design and implementation of genomic solutions for organizations involved in basic and translational research, as well as drug discovery.
Prior to NextBio, Mr. Kupershmidt was the Director of Professional Services at Silicon Genetics. There he helped develop and customize software solutions for the analysis and management of high throughput data generated by genomic and proteomic technologies. Mr. Kupershmidt joined Silicon Genetics as an early stage startup and successfully worked with hundreds of academic institutions and commercial enterprises.
Previously, Mr. Kupershmidt carried out research as a geneticist at the UCSD Howard Hughes Medical Institute where he studied transcriptional mechanisms of gene expression regulation during pituitary development. Mr. Kupershmidt is currently a PhD candidate at the SciLifeLab Institute, in Stockholm, Sweden.
Deepak Singh Ph.D.
Deepak has been at Amazon Web Services for over three years, first in business development, and currently as a Principal Product Manager responsible for Amazon EC2 instance platforms and High Performance Computing. Prior to his time at AWS, Deepak has worked in algorithm development, product management and product strategy at GeneFormatics, Accelrys and Rosetta Biosoftware respectively. He currently serves on the Scientific Advisory Board of Ensembl. Deepak has a Ph.D. in Chemistry from Syracuse University.